Olema (NASDAQ: OLMA) CMO awarded time-based and performance stock options

Rhea-AI Filing Summary

Olema Pharmaceuticals, Inc. reported that Chief Medical Officer Naseem Zojwalla received two stock option awards on February 2, 2026. She was granted stock options for 250,000 shares of common stock at an exercise price of $25.65 per share, vesting 25% on February 2, 2027 and then in equal monthly installments over the following 36 months, contingent on continued service.

She also received performance stock options covering 106,250 shares at the same exercise price. These are eligible to vest in two performance periods running from February 2, 2026 through December 31, 2029 and December 31, 2030, based on the company’s stock trading above specified price thresholds over a 30‑day average, and subject to her continued service when the Compensation Committee certifies achievement.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Zojwalla Naseem

Role CHIEF MEDICAL OFFICER

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	250,000	$0.00	--
Grant/Award	Performance Stock Options (Right to Buy)	106,250	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 250,000 shares (Direct); Performance Stock Options (Right to Buy) — 106,250 shares (Direct)

Footnotes (1)

1. 25% of the shares subject to the option vest on February 2, 2027, and 1/48 of the total number of shares subject to the option vest each month thereafter, subject to the Reporting Person's continuous service through each applicable vesting date. The performance-based stock options will be eligible to vest during two distinct performance periods, each beginning on February 2, 2026 and ending on December 31, 2029 and December 31, 2030, respectively, based on the Issuer's stock price trading at certain pre-determined price thresholds as measured by the average closing price per share of the Issuer's stock over a consecutive thirty (30) day trading period during each such performance period. Once a price threshold is achieved, the portion of the award related to such threshold will vest upon the date set forth in the certification by the Compensation Committee certifying that such price threshold was achieved, subject to the Reporting Person's continuous service as of the applicable certification date.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Zojwalla Naseem

(Last) (First) (Middle)

C/O OLEMA PHARMACEUTICALS, INC.

780 BRANNAN ST

(Street)

SAN FRANCISCO CA 94103

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Olema Pharmaceuticals, Inc. [ OLMA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CHIEF MEDICAL OFFICER

3. Date of Earliest Transaction (Month/Day/Year)
02/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$25.65	02/02/2026		A		250,000		(1)	02/01/2036	Common Stock	250,000	$0	250,000	D
Performance Stock Options (Right to Buy)	$25.65	02/02/2026		A		106,250		(2)	02/01/2036	Common Stock	106,250	$0	106,250	D

Explanation of Responses:

1. 25% of the shares subject to the option vest on February 2, 2027, and 1/48 of the total number of shares subject to the option vest each month thereafter, subject to the Reporting Person's continuous service through each applicable vesting date.

2. The performance-based stock options will be eligible to vest during two distinct performance periods, each beginning on February 2, 2026 and ending on December 31, 2029 and December 31, 2030, respectively, based on the Issuer's stock price trading at certain pre-determined price thresholds as measured by the average closing price per share of the Issuer's stock over a consecutive thirty (30) day trading period during each such performance period. Once a price threshold is achieved, the portion of the award related to such threshold will vest upon the date set forth in the certification by the Compensation Committee certifying that such price threshold was achieved, subject to the Reporting Person's continuous service as of the applicable certification date.

	/s/ Shawnte Mitchell, Attorney-in-Fact	02/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Olema Pharmaceuticals (OLMA) disclose in this Form 4 filing?

Olema disclosed option grants to its Chief Medical Officer, Naseem Zojwalla, on February 2, 2026. She received time-based stock options for 250,000 shares and performance stock options for 106,250 shares, both tied to Olema common stock and service-based conditions.

How many stock options were granted to the Olema (OLMA) Chief Medical Officer?

The Chief Medical Officer received options on a total of 356,250 shares of Olema common stock. This includes 250,000 time-based stock options and 106,250 performance stock options, each representing the right to buy shares if vesting and exercise conditions are satisfied.

What is the vesting schedule for the 250,000 Olema (OLMA) time-based stock options?

For the 250,000 time-based options, 25% vest on February 2, 2027. The remaining 75% vest in equal monthly installments over the following 36 months, conditioned on the Chief Medical Officer’s continuous service through each vesting date.

How do the performance stock options for Olema (OLMA) vest?

The 106,250 performance stock options may vest in two performance periods from February 2, 2026 to December 31, 2029 and December 31, 2030. Vesting depends on Olema’s stock trading above set price thresholds over a 30-day average and Compensation Committee certification.

What is the exercise price of the Olema (OLMA) stock options granted?

Both the time-based and performance stock options carry an exercise price of $25.65 per share. This is the price at which the Chief Medical Officer can purchase Olema common stock upon vesting and exercise of the options, subject to the stated conditions.

How long do the Olema (OLMA) stock options remain exercisable?

Both sets of options have an expiration date of February 1, 2036. Any portion that has satisfied its vesting or performance conditions before expiration may be exercisable, subject to plan terms and the Chief Medical Officer’s continued service.